PPARA rs1800202: What Your Genotype Means
The rs1800202 single nucleotide polymorphism is a missense variation in the PPARA gene, widely known in scientific literature as the Leu162Val polymorphism. It alters the structure of the peroxisome proliferator-activated receptor alpha, a key nuclear transcription factor governing lipid homeostasis and fatty acid breakdown. Genetic association studies indicate that this variant can modulate fasting triglyceride and cholesterol levels, often through notable gene-diet interactions with polyunsaturated fatty acids.
What each genotype means
Typical PPARA activity
This genotype represents the most common form of the PPARA gene, often referred to as the Leu162 allele. Research suggests this version of the protein functions normally in regulating lipid metabolism, though individual responses to dietary fats can still vary based on other genetic and lifestyle factors.
This is the most common genotype in most populations, particularly in European ancestries where the minor allele is less frequent.
Altered lipid response potential
Carrying one copy of the Val162 allele (the G allele) may influence how your body processes triglycerides and cholesterol in response to dietary polyunsaturated fatty acids. Studies have shown this variant can modulate PPARA transactivation activity, though the clinical significance remains limited and inconsistent across different studies. Please discuss your dietary patterns and lipid profile with your clinician or a registered dietitian.
This genotype is found in roughly 5-10% of individuals of European ancestry and is very rare in East Asian populations.
Increased lipid response sensitivity
Carrying two copies of the Val162 allele (the G allele) is associated with functional changes in the PPARA protein, which plays a key role in lipid metabolism. Research indicates this genotype may alter your metabolic response to dietary fats, specifically polyunsaturated fatty acids, compared to those without the variant. Because the evidence is limited and associations with health outcomes are inconsistent, you should consult with a healthcare provider to interpret these findings in the context of your overall health.
This genotype is uncommon, occurring in a small fraction of individuals of European ancestry and is extremely rare or absent in many other global populations.
What Is rs1800202 and Where Is It Located?
The single nucleotide polymorphism rs1800202 is located in the human PPARA gene on chromosome 22. It represents a transversion where the reference G allele is substituted by a C allele on the forward strand. This change results in an amino acid substitution in the encoded protein, swapping leucine for valine at position 162, historically referred to as Leu162Val or L162V. The substitution sits directly within the DNA-binding domain of the receptor. Because the DNA-binding domain is essential for recognizing specific promoter elements on target genes, structural alterations in this region can impact how effectively the receptor transcribes downstream metabolic enzymes. While the physical alteration is subtle, it has made rs1800202 one of the most thoroughly investigated candidate variants in human nutritional genomics and metabolic research.
The Biological Role of the PPARA Gene
The PPARA gene encodes the peroxisome proliferator-activated receptor alpha (PPAR-alpha), a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. PPAR-alpha acts as a master regulator of systemic lipid metabolism, predominantly active in tissues with high fatty acid catabolism such as the liver, skeletal muscle, and heart. When cellular fatty acids or therapeutic ligands like fibrates bind to PPAR-alpha, it forms a heterodimer with the retinoid X receptor (RXR). This activated complex binds peroxisome proliferator response elements (PPREs) in the promoter regions of target genes, turning on molecular pathways responsible for fatty acid uptake, beta-oxidation, and high-density lipoprotein (HDL) synthesis. Consequently, genetic variation in PPARA can influence how the human body processes circulating fats during fed and fasting states.
Research Findings and Evidence Strength
Research linking rs1800202 to cardiovascular risk markers highlights a complex relationship between genetics and diet. Multiple observational cohorts, including analyses from the Framingham Heart Study, observed that carriers of the minor C allele (encoding valine) exhibit different circulating triglyceride and apolipoprotein C-III concentrations depending on their intake of dietary polyunsaturated fatty acids (PUFAs). When PUFA intake is low, carriers have frequently demonstrated higher baseline triglycerides compared to non-carriers; however, this disadvantage often disappears or reverses when dietary PUFA intake is elevated. Despite these compelling nutrigenomic findings, the overall evidence strength for rs1800202 is categorized as limited. Large-scale genome-wide association studies (GWAS) show that rs1800202 exerts modest statistical effects that can vary across different ancestral backgrounds and lifestyle contexts.
Ancestry and Global Distribution
The prevalence of the rs1800202 variant exhibits significant variation across continental populations according to global genomic databases like gnomAD and the 1000 Genomes Project. The minor C allele is most frequently identified in populations of European ancestry, where the minor allele frequency typically ranges between 5% and 10%. Consequently, roughly 10% to 20% of European individuals carry at least one copy of the variant allele. In contrast, the C allele is exceedingly uncommon in East Asian populations, frequently registering at frequencies below 1%. Intermediate or low frequencies are observed across Admixed American, African, and South Asian cohorts. These distinct population frequencies mean that conclusions drawn from European nutritional cohorts cannot be universally generalized without careful replication in diverse demographic groups.
Practical Takeaways and Clinical Limitations
Understanding your rs1800202 genotype provides an interesting window into personal lipid biology, but it cannot be used to diagnose dyslipidemia or cardiovascular disease. In clinical practice, standard blood panels measuring total cholesterol, LDL, HDL, and triglycerides remain the cornerstone of cardiovascular risk assessment, far outweighing single genetic markers. Although research suggests that dietary fat quality—specifically consuming adequate polyunsaturated fats from sources like fish, nuts, and seed oils—may interact beneficially with this variant, individuals should not make radical dietary changes based solely on genotype. Furthermore, while PPAR-alpha is the biological target of fibrate medications, genetic testing of rs1800202 is not currently recommended by clinical guidelines for prescribing drugs. Any concerns regarding lipid levels or medical regimens should always be addressed directly with a physician.
How common is this variant?
The minor C allele of rs1800202 occurs at an approximate frequency of 5% to 10% in individuals of European descent, while it is rare in East Asian populations with a frequency of less than 1%.
Frequently asked questions
What does having the rs1800202 variant mean for my health?
Carrying the rs1800202 variant means you have a common structural variation in your PPARA gene that may subtly influence how your body metabolizes dietary fats. It is not a genetic defect or a direct cause of disease, but rather a trait associated with differences in blood triglyceride and cholesterol responses.
Does rs1800202 determine whether I should take fibrate medications?
No, rs1800202 is not used in clinical guidelines to select or dose fibrate medications. Even though fibrates act through the PPAR-alpha pathway, you should always rely on your doctor's assessment of your lipid panel and clinical history when discussing cardiovascular therapies.
Can diet offset the metabolic effects associated with this SNP?
Several observational studies indicate that dietary habits play a large role in how this variant manifests. Specifically, consuming diets with adequate polyunsaturated fatty acids (PUFAs), such as omega-3 and omega-6 fats, has been associated with more favorable triglyceride profiles in carriers of the C allele.
Is the rs1800202 variant rare?
Its rarity depends on your ancestral background. The variant is relatively common in European lineages, where up to one in ten chromosomes carries it, but it is considered rare in East Asian and African populations.
Sources & further reading
Educational information only, last refreshed 9/9/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1800202?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in PPARA
The PPARA Leu162Val missense substitution modulates fasting triglyceride levels and individual lipid responses to dietary polyunsaturated fatty acid (PUFA) intake.
Intron variant in PPARA associated with lipid substrate utilization and submaximal aerobic exercise capacity.
The Leu162Val variant in PPARA modulates lipid response and triglyceride clearance in response to dietary PUFA intake.
Intronic regulatory polymorphism in PPARA associated with lipid metabolism and cardiovascular fitness profiles.
Influences PPARA expression and is associated with variations in cholesterol levels and response to dietary fat intake.
This SNP is associated with the capacity to improve VO2max in response to endurance training and metabolic efficiency.